Vizsgálati helyszín
Budapesti Bajcsy-Zsilinszky Korhaz Es Rendelointezet
Budapest, 1106, MagyarországEU-13 felzárkózó országMég nincs intézményhez kötve
- 20futó vizsgálat
- 8lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 29 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis18 vizsgálat
- 2. fázis5 vizsgálat
- 2/3. fázis5 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz9 vizsgálat
- Toboroz9 vizsgálat
- Lezárult8 vizsgálat
- Még nem toboroz2 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Bayer2 vizsgálat
- Biohaven Therapeutics Ltd.2 vizsgálat
- Boehringer Ingelheim2 vizsgálat
- Merck Sharp & Dohme LLC2 vizsgálat
- Novartis Pharma AG2 vizsgálat
- és még 18
Futó vizsgálatok
Még nem toboroz
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
2026-526648-11-00· 2/3. fázis· Shenzhen Oculgen Biomedical Technology Co. Ltd.· Forrás
Toboroz
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025-523938-10-00· 3. fázis· Eyepoint Inc.· Forrás
Toboroz
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
2025-522231-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Toboroz
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00· 3. fázis· 4d Molecular Therapeutics Inc.· Forrás
Toboroz
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· 2. fázis· ONL Therapeutics· Forrás
Toboroz
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· 2. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· 2/3. fázis· EyeBiotech Ltd.· Forrás
Fut, nem toboroz
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· 3. fázis· EyePoint Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· 2/3. fázis· Eyebiotech Limited· Forrás
Fut, nem toboroz
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· 3. fázis· Annexon, Inc.· Forrás
Meghívásos bevonás
Long-term Safety and Tolerability of BHV-7000
NCT06443463· 2. fázis· Biohaven Therapeutics Ltd.· Forrás
Toboroz
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· 2/3. fázis· DiaMedica Therapeutics Inc· Forrás
Fut, nem toboroz
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· 3. fázis· Janssen Pharmaceutica N.V., Belgium· Forrás
Fut, nem toboroz
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS
2023-507906-15-00· 3. fázis· Novartis Pharma AG· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek